Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
133.75
-0.63 (-0.47%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Ascendis Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 329.02 | 266.72 | 51.17 | 7.78 | 6.95 | 13.38 | Upgrade
|
| Revenue Growth (YoY) | 322.18% | 421.20% | 557.93% | 11.87% | -48.01% | 26.41% | Upgrade
|
| Cost of Revenue | 47.34 | 44.4 | 12.14 | 3.52 | - | - | Upgrade
|
| Gross Profit | 281.68 | 222.32 | 39.04 | 4.26 | 6.95 | 13.38 | Upgrade
|
| Selling, General & Admin | 264.65 | 264.41 | 221.23 | 160.18 | 76.67 | 48.47 | Upgrade
|
| Research & Development | 378.03 | 413.45 | 379.62 | 295.87 | 260.9 | 191.62 | Upgrade
|
| Operating Expenses | 642.68 | 677.86 | 600.85 | 456.05 | 337.57 | 240.09 | Upgrade
|
| Operating Income | -361 | -455.54 | -561.81 | -451.79 | -330.62 | -226.72 | Upgrade
|
| Interest Expense | -136.09 | -44.07 | -30.68 | -3.91 | -1.92 | -1.22 | Upgrade
|
| Interest & Investment Income | - | 16.86 | 7.43 | 0.69 | 1.81 | 10.06 | Upgrade
|
| Earnings From Equity Investments | -22.96 | -18.4 | -17.7 | 12.04 | -9.52 | -8.11 | Upgrade
|
| Currency Exchange Gain (Loss) | 12.35 | 12.35 | 40.43 | 59.03 | -78.92 | 7.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 14.65 | 14.65 | -15.48 | - | - | - | Upgrade
|
| Pretax Income | -493.05 | -474.14 | -577.82 | -383.94 | -419.17 | -218.25 | Upgrade
|
| Income Tax Expense | 8.51 | 7.3 | 5.38 | -0.37 | -0.22 | -0.23 | Upgrade
|
| Net Income | -501.57 | -481.45 | -583.19 | -383.58 | -418.96 | -218.02 | Upgrade
|
| Net Income to Common | -501.57 | -481.45 | -583.19 | -383.58 | -418.96 | -218.02 | Upgrade
|
| Shares Outstanding (Basic) | 56 | 56 | 56 | 55 | 51 | 47 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 56 | 56 | 55 | 51 | 47 | Upgrade
|
| Shares Change (YoY) | 1.02% | 0.38% | 2.37% | 8.21% | 8.84% | 13.20% | Upgrade
|
| EPS (Basic) | -8.88 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | Upgrade
|
| EPS (Diluted) | -8.88 | -8.55 | -10.40 | -7.00 | -8.28 | -4.69 | Upgrade
|
| Free Cash Flow | -423.46 | -469.8 | -510.19 | -441.35 | -291.41 | -181.1 | Upgrade
|
| Free Cash Flow Per Share | -7.50 | -8.35 | -9.10 | -8.06 | -5.76 | -3.89 | Upgrade
|
| Gross Margin | 85.61% | 83.36% | 76.28% | 54.71% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -109.72% | -170.79% | -1097.85% | -5808.59% | -4755.07% | -1695.10% | Upgrade
|
| Profit Margin | -152.44% | -180.51% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -128.70% | -176.14% | -996.97% | -5674.38% | -4191.11% | -1353.98% | Upgrade
|
| EBITDA | -354.52 | -448.99 | -556.04 | -436.85 | -321.17 | -225.27 | Upgrade
|
| EBITDA Margin | -107.75% | -168.34% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 6.48 | 6.55 | 5.77 | 14.95 | 9.45 | 1.45 | Upgrade
|
| EBIT | -361 | -455.54 | -561.81 | -451.79 | -330.62 | -226.72 | Upgrade
|
| EBIT Margin | -109.72% | -170.79% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template.